Decoy Therapeutics

DCOY · NASDAQ

$1.14−$0.035 (−2.99%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.17

About DCOY

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Employees: 11
Headquarters: Houston, Texas
Listed: Jan 29, 2015
Sector: Health Care
Industry: Biotechnology
Website: salariuspharma.com

Leadership

Decoy Therapeutics executives
Name	Title	Since	Age
William McVicar	—	2017	67
Frederick Pierce	—	2025	64
Mark Rosenblum	—	—	72
Barbara Hibner	—	—	64
Peter Marschel	—	—	51
David Arthur	—	2019	62
Tess Burleson	—	—	58
Arnold Hanish	—	—	77
Paul Lammers	—	—	67
Jonathan Lieber	—	—	56
Maureen McEnroe	—	2022	—

Similar companies

Companies in the same industry as Decoy Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.